YU48722B - Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika - Google Patents
Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotikaInfo
- Publication number
- YU48722B YU48722B YU92192A YU92192A YU48722B YU 48722 B YU48722 B YU 48722B YU 92192 A YU92192 A YU 92192A YU 92192 A YU92192 A YU 92192A YU 48722 B YU48722 B YU 48722B
- Authority
- YU
- Yugoslavia
- Prior art keywords
- matter
- antibiotic
- compositions
- olygosaharide
- lypophile
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika, naznačen time, što se (a) lipofilni oligosaharidni antibiotik predstavljen formulom (I) u kojoj je: X predstavlja NO2, NO, NH2, NHCOCH3, NHOH, NH(C2H5), N(C2H5)2, OH ili vodonik, R2 je CH3, COCH(CH3)2, COCH3, CO(CH2)3CH3, COCH2CH3 ili vodonik, R3 je CH3 ili vodonik, R4 predstavlja COCH3, CH(OCH3)(CH3), CH(OH)CH3 ili vodonik, R6 je CH3 ili vodonik, R7 je CH3 ili vodonik, R8 predstavlja CH3, CH2OH ili vodonik, R9 je CH3 ili vodonik, Y je OH, CH3 ili vodonik, W je hlor ili vodonik i Z je hlor ili vodonik, meša sa (b) najmanje jednom približno stehiometrijskom količinom baze koja je sposobna da gradi farmaceutski prihvatljivu so sa lipofilnim oligosaharidnim antibiotikom formule (I), (c) oko 1-15 molova hidroksipropil-α-ciklodekstrina po molu antibiotika formule (I), ili oko 1-9, poželjno oko 2-6 molova hidroksipropil-Гџ-ciklodekstrina po molu antibiotika formule (I), ili oko 2-8, poželjno oko 3-5 molova hidroksipropil-γ-ciklodekstrina po molu antibiotika formule (I), pri čemu pomenuti -α-, -Гџ- i -γ-ciklodekstrin imaju svaki po oko 2 do oko 15 hidroksipropil grupa po molu pomenutog -α-, -Гџ- i -γ-ciklodekstrina i (d) od 0 do 6,0 mas.% (na bazi količine antibiotika formule (I)) farmaceutski prihvatljivog nejonskog površinski aktivnog sredstva. - Prijava sadrži još 2 nezavisna i 5 zavisnih zahteva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77786491A | 1991-10-16 | 1991-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
YU92192A YU92192A (sr) | 1996-01-09 |
YU48722B true YU48722B (sh) | 1999-07-28 |
Family
ID=25111545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU92192A YU48722B (sh) | 1991-10-16 | 1992-10-14 | Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika |
Country Status (27)
Country | Link |
---|---|
US (1) | US5624914A (sh) |
EP (2) | EP0538011B1 (sh) |
JP (1) | JP2614407B2 (sh) |
KR (1) | KR100249584B1 (sh) |
CN (1) | CN1035923C (sh) |
AT (1) | ATE156019T1 (sh) |
AU (1) | AU678344B2 (sh) |
CA (1) | CA2121345C (sh) |
DE (1) | DE69221252T2 (sh) |
DK (1) | DK0538011T3 (sh) |
ES (1) | ES2104845T3 (sh) |
FI (1) | FI941723A (sh) |
GR (1) | GR3024800T3 (sh) |
HK (1) | HK1001085A1 (sh) |
HR (1) | HRP921069B1 (sh) |
HU (1) | HUT75157A (sh) |
IL (1) | IL103446A (sh) |
MX (1) | MX9205922A (sh) |
NO (1) | NO307326B1 (sh) |
NZ (1) | NZ244735A (sh) |
PH (1) | PH31675A (sh) |
PL (1) | PL170591B1 (sh) |
SI (1) | SI9200260A (sh) |
TW (1) | TW221378B (sh) |
WO (1) | WO1993007904A1 (sh) |
YU (1) | YU48722B (sh) |
ZA (1) | ZA927923B (sh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380172B1 (en) | 1991-10-16 | 2002-04-30 | Schering Corporation | Monomeric lipophilic oligosaccharide antibiotic compositions |
US5948688A (en) * | 1991-10-16 | 1999-09-07 | Schering Corporation | Method of determining monomeric drug content |
US5652226A (en) * | 1995-12-22 | 1997-07-29 | Schering Corporation | Water soluble antibiotics |
US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
US5763600A (en) * | 1997-04-18 | 1998-06-09 | Schering Corporation | Oligosaccharide antibiotics and process for preparation thereof |
JP2001518556A (ja) * | 1997-10-03 | 2001-10-16 | ガレニカ ファーマシューティカルズ, インコーポレイテッド | イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用 |
US6162910A (en) * | 1998-11-30 | 2000-12-19 | Schering Corporation | Process for preparing lipophilic oligosaccharide antibiotics |
CO5231233A1 (es) * | 1998-12-18 | 2002-12-27 | Cherinf Corp | Proceso para recuperar antibioticos oligosacaridos lipofilic lipofilicos |
US6320044B1 (en) | 1998-12-18 | 2001-11-20 | Schering Corporation | Process for recovering lipophilic oligosaccharide antibiotics |
WO2001039573A2 (de) * | 1999-12-01 | 2001-06-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Verwendung von lungensurfactant zur behandlung von legionärskrankheit |
US6861513B2 (en) | 2000-01-12 | 2005-03-01 | Schering Corporation | Everninomicin biosynthetic genes |
CA2726789A1 (en) * | 2000-02-05 | 2001-11-08 | Theravance, Inc. | Cyclodextrin containing glycopeptide antibiotic compositions |
US6699505B2 (en) * | 2000-10-17 | 2004-03-02 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by compexing with cyclodextrins |
DE10109166A1 (de) * | 2001-02-25 | 2002-09-12 | Combinature Biopharm Ag | Avilamycin-Derivate |
EP1730163A4 (en) * | 2004-03-17 | 2009-12-30 | Panacos Pharmaceuticals Inc | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid |
US7819377B2 (en) * | 2004-12-01 | 2010-10-26 | Nitto Denko Corporation | Foam filling member |
ES2383534T3 (es) * | 2005-04-12 | 2012-06-22 | Myrexis, Inc. | Polimorfos de di-N-metil-D-glucamina del ácido 3-O-(3',3'-dimetilsuccinil)betulínico |
KR20160005378A (ko) | 2007-09-14 | 2016-01-14 | 사노피 파스테르 바이오로직스, 엘엘씨 | 클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물 |
JP2010095454A (ja) * | 2008-10-14 | 2010-04-30 | Cyclochem:Kk | 抗菌組成物 |
EP4324483A3 (en) * | 2011-01-14 | 2024-05-01 | Emory University | Oligosaccharide conjugates for targeting bacteria and uses related thereto |
WO2016201137A1 (en) | 2015-06-10 | 2016-12-15 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
CN106317143B (zh) * | 2016-08-23 | 2020-10-30 | 河北圣雪大成制药有限责任公司 | 一种提取阿维拉霉素的方法 |
WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
CN117024611B (zh) * | 2023-03-01 | 2024-05-17 | 中国科学院南海海洋研究所 | 寡糖类抗生素everninomicin高产菌株的构建及活性的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR128F (sh) * | 1962-04-02 | |||
US3915956A (en) * | 1973-07-09 | 1975-10-28 | Schering Corp | Reduction products of everninomicins and methods for their manufacture |
US3920629A (en) * | 1973-09-19 | 1975-11-18 | Schering Corp | Desevernitrose everninomicins and method for their manufacture |
US4006225A (en) * | 1973-10-31 | 1977-02-01 | Schering Corporation | Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor |
US3998708A (en) * | 1976-01-19 | 1976-12-21 | Schering Corporation | Electrochemical process for preparing hydroxylaminoeverninomicins |
US4027016A (en) * | 1976-01-19 | 1977-05-31 | Schering Corporation | Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor |
US4129720A (en) * | 1977-02-14 | 1978-12-12 | Schering Corporation | Aminoeverninomicin and derivatives thereof |
US4597968A (en) * | 1982-08-06 | 1986-07-01 | Schering Corporation | Antibiotic 13-384 complex from Micromonospora carbonacea var africana |
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4735903A (en) * | 1984-06-21 | 1988-04-05 | Schering Corporation | Micromonospora carbonacea var africana |
US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
US4767748A (en) * | 1985-10-15 | 1988-07-30 | Schering Corporation | Substituted oligosaccharide antibodies |
US4622314A (en) * | 1985-10-15 | 1986-11-11 | Schering Corporation | Substituted oligosaccharide antibiotics |
US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
-
1992
- 1992-10-14 YU YU92192A patent/YU48722B/sh unknown
- 1992-10-14 WO PCT/US1992/008565 patent/WO1993007904A1/en not_active Application Discontinuation
- 1992-10-14 AU AU27806/92A patent/AU678344B2/en not_active Ceased
- 1992-10-14 EP EP92309368A patent/EP0538011B1/en not_active Expired - Lifetime
- 1992-10-14 PL PL92303189A patent/PL170591B1/pl unknown
- 1992-10-14 CA CA002121345A patent/CA2121345C/en not_active Expired - Fee Related
- 1992-10-14 HU HU9401104A patent/HUT75157A/hu unknown
- 1992-10-14 ES ES92309368T patent/ES2104845T3/es not_active Expired - Lifetime
- 1992-10-14 PH PH45109A patent/PH31675A/en unknown
- 1992-10-14 US US08/211,700 patent/US5624914A/en not_active Expired - Lifetime
- 1992-10-14 EP EP92921991A patent/EP0610295A1/en active Pending
- 1992-10-14 DE DE69221252T patent/DE69221252T2/de not_active Expired - Fee Related
- 1992-10-14 AT AT92309368T patent/ATE156019T1/de not_active IP Right Cessation
- 1992-10-14 DK DK92309368.6T patent/DK0538011T3/da active
- 1992-10-14 KR KR1019940701247A patent/KR100249584B1/ko not_active IP Right Cessation
- 1992-10-14 NZ NZ244735A patent/NZ244735A/en unknown
- 1992-10-14 JP JP5507719A patent/JP2614407B2/ja not_active Expired - Lifetime
- 1992-10-14 TW TW081108170A patent/TW221378B/zh active
- 1992-10-14 ZA ZA927923A patent/ZA927923B/xx unknown
- 1992-10-15 CN CN92112388A patent/CN1035923C/zh not_active Expired - Fee Related
- 1992-10-15 IL IL10344692A patent/IL103446A/xx not_active IP Right Cessation
- 1992-10-15 MX MX9205922A patent/MX9205922A/es not_active IP Right Cessation
- 1992-10-16 HR HR07/777,864A patent/HRP921069B1/xx not_active IP Right Cessation
- 1992-10-16 SI SI19929200260A patent/SI9200260A/sl unknown
-
1994
- 1994-04-08 NO NO941276A patent/NO307326B1/no not_active IP Right Cessation
- 1994-04-14 FI FI941723A patent/FI941723A/fi unknown
-
1997
- 1997-09-19 GR GR970402434T patent/GR3024800T3/el unknown
-
1998
- 1998-01-09 HK HK98100167A patent/HK1001085A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU48722B (sh) | Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika | |
HUT61989A (en) | Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient | |
ZA928170B (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid | |
NZ241873A (en) | Film-coated solid dosage formulation comprising 3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulphonamide | |
AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
PL299870A1 (en) | 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae | |
AU2905092A (en) | Pharmaceutical dipeptide compositions and methods of use thereof | |
HUT64013A (en) | Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
UA42733C2 (uk) | Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить | |
HUT49614A (en) | Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds | |
HUT50334A (en) | Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient | |
GR890100833A (en) | Process for the preparation of a compound with gastric inhibitopy effect | |
HUT61743A (en) | Process for producing 2-(piperidin-1-yl)-ethanol derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
AP9801235A0 (en) | Erythromycin derivatives. | |
IL97648A0 (en) | Stabilized 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof | |
IE43125L (en) | Aminoglycoside derivative | |
HUT61740A (en) | Process for producing 2-piperidinyl-pyrimidine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
IL57513A0 (en) | 1,3-diaminopropan-2-ol derivatives,their preparation and pharmaceutical compositions containing them | |
HUT62567A (en) | Process for producing benzoquinoxaline derivatives and pharmaceutical compositions comprising same as active ingredient | |
HUT59936A (en) | Process for producing 10,11,12,13-tetrahydro-demicosin derivatives and pharmaceutical compositions containing them as active components |